Report primary analysis results by independent central review from the IGNYTE anti-PD-1 failed melanoma cohort
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Jun 2024
- Due
- 30 Jun 2024
- Delivered
- June 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Primary analysis results by independent central review from the IGNYTE anti-PD-1 failed melanoma cohort are expected later in Q2 2024”
What we found
Evidence strength A What the grades mean
The company reported positive topline primary analysis data from the IGNYTE anti-PD-1 failed melanoma cohort in June 2024, meeting the Q2 2024 deadline.
-
A Replimune Group, Inc. 8-K filed 2024-08-08
“In June, the Company announced positive topline primary analysis data by independent central review from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma.” ✓ confirmed on the page
-
A Replimune Group, Inc. 10-Q filed 2024-08-08
“RP1 is currently under development in multiple clinical trials, the most advanced being the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial, that, as reported in June 2024, had positive topline primary data analysis” ✓ confirmed on the page
Market reaction: the shares moved +1.0% against the S&P 500 over the three sessions around the disclosure (7 Aug 2024 to 12 Aug 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Primary analysis results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-REPL-002734 · Corrections policy